Clarinase Repetabs (5 mg / 120 mg) is an oral combination therapeutic medication formulated for the symptomatic relief of seasonal allergic rhinitis, perennial allergic rhinitis, and upper respiratory congestion associated with the common cold.
Unlike topical nasal sprays, Clarinase Repetabs delivers systemically acting active ingredients via a dual-action, extended-release tablet formulation (repetab technology). This dual component addresses both histamine-mediated allergic reactions (sneezing, rhinorrhea, itchy eyes) and vascular mucosal congestion within the nasal passages and paranasal sinuses.
Active Ingredients & Mechanism of Action
Clarinase Repetabs integrates two synergistic active pharmaceutical ingredients engineered to provide continuous symptomatic relief:
1. Loratadine (5 mg)
Pharmacological Class: Non-sedating second-generation H1 receptor antagonist.
2. Pseudoephedrine Sulfate (120 mg)
Pharmacological Class: Sympathomimetic amine / systemic nasal decongestant.
Extended-Release Delivery System
The tablet consists of an outer coating designed for immediate release of Loratadine (5 mg) and an initial portion of Pseudoephedrine (60 mg), paired with an inner core that releases the remaining Pseudoephedrine (60 mg) several hours later. This dual-release mechanism maintains steady therapeutic plasma levels over a 12-hour period.
Key Clinical Indications & Benefits
Clarinase Repetabs is indicated for adult and pediatric patients (12 years and older) experiencing multi-symptom upper respiratory discomfort:
Relief of Nasal Decongestion: Promotes drainage of paranasal sinuses and clears blocked nasal passages caused by allergic rhinitis or cold viruses.
Suppression of Allergic Symptoms: Effectively mitigates sneezing, watery eyes, ocular itching, and anterior nasal discharge (rhinorrhea).
Systemic Distribution: Provides uniform relief across both upper respiratory and ocular mucosal tissues without the localized irritation or rebound congestion (rhininitis medicamentosa) associated with prolonged topical nasal decongestant sprays.
Dosing Convenience: Extended-release profile provides sustained coverage with a twice-daily dosing regimen.
Dosage & Administration Guidelines
Administer strictly according to healthcare provider guidance or package instructions:
Adults and Children Aged 12 Years and Over: One (1) tablet twice daily (every 12 hours) swallowed whole with a full glass of water.
Method of Administration: Tablets must be swallowed whole. Do not chew, crush, or break the tablet, as doing so compromises the extended-release matrix and may cause a rapid, unsafe release of Pseudoephedrine.
Duration: Use the minimum effective duration required to control symptoms. Consult a physician if symptoms persist beyond 7 days.
Safety Precautions, Contraindications & Interactions
Contraindications
Do not use Clarinase Repetabs in individuals with:
Known hypersensitivity to Loratadine, Pseudoephedrine, or adrenergic agents.
Severe hypertension (high blood pressure) or severe coronary artery disease.
Narrow-angle glaucoma or urinary retention.
Concomitant administration of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOI treatment, due to the risk of hypertensive crisis.
Precautions & Warnings
Cardiovascular & Endocrine Conditions: Use with caution in patients with mild-to-moderate hypertension, tachyarrhythmias, ischemic heart disease, hyperthyroidism, elevated intraocular pressure, or prostatic hypertrophy.
Renal or Hepatic Impairment: Patients with severe renal failure or hepatic insufficiency require dosage adjustments (typically starting with one tablet once daily); consult a physician before initiation.
Pregnancy & Lactation: Usage during pregnancy or breastfeeding should be avoided unless explicitly directed by a prescribing clinician, as Pseudoephedrine passes into human breast milk and crosses the placental barrier.
Drug InteractionsAntihypertensives: Pseudoephedrine may diminish the therapeutic effectiveness of antihypertensive medications (beta-blockers, methyldopa, reserpine).
Other Decongestants: Avoid co-administration with other systemic or topical sympathomimetic decongestants.
Storage Conditions & Technical Product Details
Storage: Store below 25°C in a cool, dry place protected from light and excessive moisture. Keep out of reach and sight of children.
Dosage Form: Oral extended-release tablet (Repetab).
Packaging: Available in blister strips of 14 tablets.
Medication
